D
Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.5832
-$0.0168-2.80%
D
Sell
12/9/2024Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 12/9/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 49.96% from -$8.48M to -$4.24M, and earnings per share increased from -$0.2572 to -$0.2475.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 12/9/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 49.96% from -$8.48M to -$4.24M, and earnings per share increased from -$0.2572 to -$0.2475.
E
Sell
7/18/2024Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 7/18/2024 due to a decline in the volatility index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 7/18/2024 due to a decline in the volatility index.
D
Sell
6/4/2024Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 6/4/2024 due to an increase in the valuation index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 6/4/2024 due to an increase in the valuation index.
E
Sell
4/17/2024Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 4/17/2024 due to a decline in the valuation index, total return index and volatility index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 4/17/2024 due to a decline in the valuation index, total return index and volatility index.
D
Sell
11/20/2023Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 11/20/2023 due to an increase in the valuation index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 11/20/2023 due to an increase in the valuation index.
E
Sell
8/15/2023Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 8/15/2023 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.3024 to -$0.5546, and EBIT declined 79.21% from -$6.74M to -$12.07M.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 8/15/2023 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.3024 to -$0.5546, and EBIT declined 79.21% from -$6.74M to -$12.07M.
D
Sell
7/19/2023Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 7/19/2023 due to an increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.3715 to -$0.3024, and EBIT increased 13.36% from -$7.77M to -$6.74M.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 7/19/2023 due to an increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.3715 to -$0.3024, and EBIT increased 13.36% from -$7.77M to -$6.74M.
E
Sell
3/31/2023Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 3/31/2023 due to a decline in the growth index, solvency index and valuation index. EBIT declined 118.19% from -$3.56M to -$7.77M, earnings per share declined from -$0.1824 to -$0.3715, and the quick ratio declined from 6.49 to 3.07.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 3/31/2023 due to a decline in the growth index, solvency index and valuation index. EBIT declined 118.19% from -$3.56M to -$7.77M, earnings per share declined from -$0.1824 to -$0.3715, and the quick ratio declined from 6.49 to 3.07.
D
Sell
3/14/2023Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to D- from D on 03/14/2023.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/1/2022Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D from D- on 11/1/2022 due to an increase in the volatility index and total return index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D from D- on 11/1/2022 due to an increase in the volatility index and total return index.
D
Sell
9/23/2022Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 9/23/2022 due to an increase in the volatility index and total return index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 9/23/2022 due to an increase in the volatility index and total return index.
E
Sell
9/2/2022Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 9/2/2022 due to a decline in the volatility index and valuation index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 9/2/2022 due to a decline in the volatility index and valuation index.
D
Sell
8/18/2022Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 8/18/2022 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 36.15% from -$6.27M to -$4M, earnings per share increased from -$0.3988 to -$0.2892, and EBIT increased 25.91% from -$7.45M to -$5.52M.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 8/18/2022 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 36.15% from -$6.27M to -$4M, earnings per share increased from -$0.3988 to -$0.2892, and EBIT increased 25.91% from -$7.45M to -$5.52M.
E
Sell
5/24/2022Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 5/24/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1992 to -$0.3988, EBIT declined 87.92% from -$3.96M to -$7.45M, and operating cash flow declined 60.6% from -$3.9M to -$6.27M.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 5/24/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1992 to -$0.3988, EBIT declined 87.92% from -$3.96M to -$7.45M, and operating cash flow declined 60.6% from -$3.9M to -$6.27M.
D
Sell
5/5/2022Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 68.98% from -$2.31M to -$3.9M, earnings per share declined from -$0.1235 to -$0.1992, and EBIT declined 60.07% from -$2.48M to -$3.96M.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 68.98% from -$2.31M to -$3.9M, earnings per share declined from -$0.1235 to -$0.1992, and EBIT declined 60.07% from -$2.48M to -$3.96M.
D
Sell
11/3/2021Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 11/3/2021 due to a large increase in the growth index and total return index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to D- from E+ on 11/3/2021 due to a large increase in the growth index and total return index.
E
Sell
9/1/2021Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to E+ from E on 9/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 5.12 to 30.79.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to E+ from E on 9/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 5.12 to 30.79.
E
Sell
6/1/2021Upgraded
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to E from E- on 6/1/2021 due to a significant increase in the solvency index.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was upgraded to E from E- on 6/1/2021 due to a significant increase in the solvency index.
E
Sell
3/15/2021None
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E- from U on 03/15/2021.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) was downgraded to E- from U on 03/15/2021.
NASDAQ
04/08/2025 11:01AM Eastern
Quotes delayed
